Progress 06/01/16 to 05/31/17
Outputs Target Audience:During this reporting period, I presented my work in research seminars and poster sessions. This was done at individual universities, one research group at the USDA, and international scientific conferences. The audiences at the venues were generally academic reseachers interested in basic science related to bacterial infection. The USDA presentation was to academic researchers as well as government researchers within the poultry production and product safety group. I also published two open access publications during this reporting period, meaning that some of this research is available to the international community. Changes/Problems:
Nothing Reported
What opportunities for training and professional development has the project provided?I have been able to work with protein crystallographers at the University of Chicago and Vanderbilt University to solve the structure of our regulator. This has provided be with experience in the tools they use to characterize proteins at the molecular level. How have the results been disseminated to communities of interest?We have published research articles and have presented to various groups, the results of this work. What do you plan to do during the next reporting period to accomplish the goals?
Nothing Reported
Impacts What was accomplished under these goals?
1. We have been continuously working on characterizing the regulator described in this aim. The investigator we initially worked with at the University of Chicago left academia and we located another collaborator at Vanderbilt University whois currently purifiying various truncations of the regulator to determine whether they will form crystals to solve the structures - we tried to crystallize the various domains of the protein, but none of those worked as the protein isremarkablysoluble. Theyperformed proteolytic analysis to identify the regions of potential truncation and are convince their current work will result in a structure of the ligand binding domain. Additionally, we have identified tandem repeats within the promoter region of the heme utilization genes that may be used for regulator binding. We are currently creating promoter truncations to look at the ability of the regulator to specifically bind these regions. Since these repeats overlap with the ferric uptake regulator (Fur) binding sites, we are also looking at interations between Fur and our regulator (HeuR). 2. We have shown that genotypically pure mutants of the gene Cjj0812 are resistant to the small molecular inhibitors we identified in our earlier work. Additionally, we also found mutants that were resistant to these compounds that were not represented by any particular genotype. To understand the mechanism of resistance in these strains, we recently performed transcriptomics on cultures and have identified approximately three dozen genes that are differentially expressed in these mutants. We are currently following up on these various pathways, e.g. Cjj0812 is involved in processing cysteine into sulfur and alanine, to see how they impact Campylobacter resistance to our growth inhibitors.
Publications
- Type:
Journal Articles
Status:
Accepted
Year Published:
2016
Citation:
Accumulation of Peptidoglycan O-Acetylation Leads to Altered Cell Wall Biochemistry and Negatively Impacts Pathogenesis Factors of Campylobacter jejuni.
Ha R, Frirdich E, Sychantha D, Biboy J, Taveirne ME, Johnson JG, DiRita VJ, Vollmer W, Clarke AJ, Gaynor EC.
J Biol Chem. 2016 Oct 21;291(43):22686-22702. Epub 2016 Jul 29.
PMID: 27474744
- Type:
Book Chapters
Status:
Published
Year Published:
2017
Citation:
Generation and Screening of an Insertion Sequencing-Compatible Mutant Library of Campylobacter jejuni.
Johnson JG, DiRita VJ.
Methods Mol Biol. 2017;1512:257-272.
PMID: 27885613
- Type:
Journal Articles
Status:
Published
Year Published:
2016
Citation:
The PAS Domain-Containing Protein HeuR Regulates Heme Uptake in Campylobacter jejuni.
Johnson JG, Gaddy JA, DiRita VJ.
MBio. 2016 Nov 15;7(6). pii: e01691-16. doi: 10.1128/mBio.01691-16.
PMID: 27935836
|
|